Organ-on-Chip Recapitulates Thrombosis Induced by an anti-CD154 Monoclonal Antibody: Translational Potential of Advanced Microengineered Systems

Clinical Pharmacology and Therapeutics

Volumn 104, Issue 6, 2018, Pages 1240-1248

  Barrile, Riccardo ^a   van der Meer, Andries D ^b   Park, Hyoungshin ^a   Fraser, Jacob P ^a   Simic, Damir ^c   Teng, Fang ^c   Conegliano, David ^a   Nguyen, Justin ^a   Jain, Abhishek ^d,e   Zhou, Mimi ^c   Karalis, Katia ^a   Ingber, Donald E ^d   Hamilton, Geraldine A ^a   Otieno, Monicah A ^c  

^a Emulate Inc   (United States)

^b UNIVERSITY OF TWENTE   (Netherlands)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d HARVARD UNIVERSITY   (United States)

^e Texas A M University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BIOLOGICAL MARKER; CD40 LIGAND MONOCLONAL ANTIBODY; FC RECEPTOR IIA; FIBRIN; FIBRINOGEN RECEPTOR; INTEGRIN RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; CD40 LIGAND; FC RECEPTOR; FCGR2A PROTEIN, HUMAN; HU5C8 ANTIBODY; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ARTICLE; BLOOD CLOTTING; BLOOD VESSEL; BLOOD VESSEL PERMEABILITY; CELL ACTIVATION; CONTROLLED STUDY; ENDOTHELIUM; ENDOTHELIUM CELL; FEMALE; FIBRIN CLOT; FIBRIN DEPOSITION; FIBRIN FORMATION; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; MALE; PRIORITY JOURNAL; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; THROMBOSIS; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM; AUTOIMMUNE DISEASE; BLOOD; COMPARATIVE STUDY; DEVICES; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFECT; IMMUNOLOGY; LAB ON A CHIP; METABOLISM; MICROCHIP ANALYSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOCYTE;

ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOIMMUNE DISEASES; BLOOD COAGULATION; BLOOD PLATELETS; CD40 LIGAND; DRUG DESIGN; DRUG DEVELOPMENT; ENDOTHELIAL CELLS; IMMUNOLOGIC FACTORS; LAB-ON-A-CHIP DEVICES; MICROCHIP ANALYTICAL PROCEDURES; PROSPECTIVE STUDIES; RECEPTORS, IGG; RETROSPECTIVE STUDIES; RISK ASSESSMENT; THROMBOSIS;

EID: 85046131849     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.1054     Document Type: Article

References (49)

1. Daoussis, D., Andonopoulos, A.P. & Liossis, S.-N.C. Targeting CD40L: a promising therapeutic approach. Clin. Vaccine Immunol. 11, 635–641 (2004).
2. Peters, A.L., Stunz, L.L. & Bishop, G.A. CD40 and autoimmunity: the dark side of a great activator. Semin. Immunol. 21, 293–300 (2009).
3. Kirk, A.D. et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. 5, 686–693 (1999).
4. Kirk, A.D. et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. U. S. A. 94, 8789–8794 (1997).
5. Kenyon, N.S. et al. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc. Natl. Acad. Sci. U. S. A. 96, 8132–8137 (1999).
6. Elster, E.A. et al. Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates. Transplantation 72, 1473–1478 (2001).
7. Huang, W. et al. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum. 46, 1554–1562 (2002).
8. Boumpas, D.T. et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 48, 719–727 (2003).
9. Liossis, S.-N.C. & Sfikakis, P.P. Costimulation blockade in the treatment of rheumatic diseases. BioDrugs 18, 95–102 (2004).
10. Chan, A.C. & Carter, P.J. Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol. 10, 301–316 (2010).
11. Kuwana, M. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 103, 1229–1236 (2003).
12. Kimura, K. et al. Study of plasma levels of soluble CD40 ligand in systemic lupus erythematosus patients who have undergone plasmapheresis. Ther. Apher. Dial. 9, 64–68 (2005).
13. Danese, S. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 52, 1435–1441 (2003).
14. Henn, V. et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391, 591–594 (1998).
15. Prasad, K.S.S., Andre, P., Yan, Y. & Phillips, D.R. The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease. Curr. Opin. Hematol. 10, 356–361 (2003).
16. Ferroni, P. et al. Contribution of platelet-derived CD40 ligand to inflammation, thrombosis and neoangiogenesis. Curr. Med. Chem. 14, 2170–2180 (2007).
17. Duffau, P. et al. Platelet CD154 potentiates interferon-secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Sci. Transl. Med. 2, 47ra63–47ra63 (2010).
18. Xie, J.H. et al. Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases. J. Immunol. 192, 4083–4092 (2014).
19. Wakefield, I. et al. An assessment of the thromboembolic potential of CDP7657, a monovalent Fab' PEG anti-CD40L antibody, in rhesus macaques. Arthritis Rheum [abstract] 62, Suppl 10 1243 (2010).
20. Shock, A. et al. CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. Arthritis Res. Ther. 17, (2015).
21. Sidiropoulos, P.I. & Boumpas, D.T. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 13, 391–397 (2004).
22. Bhatia, S.N. & Ingber, D.E. Microfluidic organs-on-chips. Nat. Biotechnol. 32, 760–772 (2014).
23. Ingber, D.E. Reverse engineering human pathophysiology with organs-on-chips. Cell 164, 1105–1109 (2016).
24. Westein, E. et al. Atherosclerotic geometries exacerbate pathological thrombus formation poststenosis in a von Willebrand factor-dependent manner. Proc. Natl. Acad. Sci. U. S. A. 110, 1357–1362 (2013).
25. Tsai, M. et al. In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology. J. Clin. Invest. 122, 408–418 (2012).
26. Fransson, J. et al. Anti-CD154 antibodies and methods of using them. .
27. Huh, D. et al. Reconstituting organ-level lung functions on a chip. Science 328, 1662–1668 (2010).
28. Huh, D. et al. A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice. Sci. Transl. Med. 4, 159ra147–159ra147 (2012).
29. Jain, A. et al. A primary human lung alveolus-on-a-chip model of intravascular thrombosis for assessment of therapeutics. Clin. Pharmacol. Ther. (2017) doi:10.1002/cpt.742 [Epub ahead of print].
30. Yau, J.W., Teoh, H. & Verma, S. Endothelial cell control of thrombosis. BMC Cardiovasc. Disord. 15 (2015).
31. Jain, A. et al. Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endothelium. Biomed. Microdev. 18 (2016).
32. Nishizawa, E., Wynalda, D., Suydam, D., Sawa, T. & Schultz, J. Collagen-induced pulmonary thromboembolism in mice. Thromb. Res. 1, 233–241 (1972).
33. Cines, D.B. et al. Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin. Blood 123, 1596–1603 (2014).
34. Tutwiler, V., Wang, H., Litvinov, R.I., Weisel, J.W. & Shenoy, V.B. Interplay of platelet contractility and elasticity of fibrin/erythrocytes in blood clot retraction. Biophys. J. 112, 714–723 (2017).
35. Bester, J. & Pretorius, E. Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity. Sci. Rep. 6, (2016).
36. Monroe, D.M. Platelets and thrombin generation. Arterioscler. Thromb. Vasc. Biol. 22, 1381–1389 (2002).
37. Jung, S.M. & Moroi, M. Platelets interact with soluble and insoluble collagens through characteristically different reactions. J. Biol. Chem. 273, 14827–14837 (1998).
38. Phillips, D.R. & Scarborough, R.M. Clinical pharmacology of eptifibatide. Am. J. Cardiol. 80, 11B–20B (1997).
39. Hagemeyer, C.E. & Peter, K. Targeting the platelet integrin GPIIb/IIIa. Curr. Pharm. Des. 16, 4119–4133 (2010).
40. Karpusas, M. et al. Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody. Structure 9, 321–329 (2001).
41. Robles-Carrillo, L. et al. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J. Immunol. 185, 1577–1583 (2010).
42. Kato, K. et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J. Clin. Invest. 104, 947–955 (1999).
43. dela Paz, N.G. & D'Amore, P.A. Arterial versus venous endothelial cells. Cell Tissue Res. 335, 5–16 (2009).
44. Speiser, W. et al. D-dimer and TAT measurement in patients with deep venous thrombosis: utility in diagnosis and judgement of anticoagulant treatment effectiveness. Thromb. Haemost. 64, 196–201 (1990).
45. Inoh, M., Tokuda, M., Kiuchi, H., Kurata, N. & Takahara, J. Evaluating systemic lupus erythematosus disease activity using molecular markers of hemostasis. Arthritis Rheum. 39, 287–291 (1996).
46. Langer, F. et al. The role of CD40 in CD40L- and antibody-mediated platelet activation. Thromb. Haemost. 93, 1137–1146 (2005).
47. Vafa, O. et al. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods 65, 114–126 (2014).
48. Prasad, K.S.S. et al. Soluble CD40 ligand induces 3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc. Natl. Acad. Sci. U. S. A. 100, 12367–12371 (2003).
49. Simic, D., Bogdan, N., Teng, F. & Otieno, M. Blocking α5β1 integrin attenuates sCD40L-mediated platelet activation. Clin. Appl. Thromb. Hemost. 23, 607–614 (2017).